Patents Examined by Zachary C. Howard
  • Patent number: 10968268
    Abstract: The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: April 6, 2021
    Assignee: H. LUNDBECK A/S
    Inventors: Maria-Cristina Loomis, Leon F. Garcia-Martinez, Benjamin H. Dutzar, Daniel S. Allison, Katherine Lee Hendrix, Ethan W. Ojala, Pei Fan, Jeffrey T. L. Smith, John A. Latham, Charlie Karasek, Jenny Mulligan, Michelle Scalley-Kim, Erica Stewart, Vanessa Lisbeth Rubin, Jens J. Billgren
  • Patent number: 10959939
    Abstract: The present invention relates to novel liquid protein formulations, particularly arginine-free liquid pharmaceutical compositions of etanercept. The invention employs particular combinations and classes of buffer systems, tonicifiers, and sugar stabilisers, optionally alongside polar ionisable amino acids (e.g. aspartic acid, glutamic acid, histidine, and lysine), to afford a viable and storable drug product.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: March 30, 2021
    Assignee: ARES TRADING S.A.
    Inventors: Angelika Freitag, Andrea Hawe, Gianluca Rinaldi, Alessandra Del Rio
  • Patent number: 10954279
    Abstract: The disclosure provides, in part, follistatin polypeptides that are suitable for use in local administration and methods for use.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: March 23, 2021
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, Asya Grinberg
  • Patent number: 10954285
    Abstract: The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: March 23, 2021
    Assignee: H. LUNDBECK A/S
    Inventors: Maria-Cristina Loomis, Leon F. Garcia-Martinez, Benjamin H. Dutzar, Daniel S. Allison, Katherine Lee Hendrix, Ethan W. Ojala, Pei Fan, Jeffrey T. L. Smith, John A. Latham, Charlie Karasek, Jenny Mulligan, Michelle Scalley-Kim, Erica Stewart, Vanessa Lisbeth Rubin, Jens J. Billgren
  • Patent number: 10947310
    Abstract: The present invention provides apelin receptor (APLNR) modulators that bind to APLNR and methods of using the same. The invention includes APLNR modulators such as antibodies, or antigen-binding fragments thereof, which inhibit or attenuate APLNR-mediated signaling. The invention includes APLNR modulators such as antibodies, or antibody fusion proteins thereof, that activate APLNR-mediated signaling. According to certain embodiments of the invention, the antibodies or antigen-binding fragments or antibody fusion proteins are fully human antibodies that bind to human APLNR with high affinity. The APLNR modulators of the invention are useful for the treatment of diseases and disorders associated with APLNR signaling and/or APLNR cellular expression, such as cardiovascular diseases, angiogenesis diseases, metabolic diseases and fibrotic diseases.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: March 16, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Panayiotis Stevis, Andrew J. Murphy, Jesper Gromada, Yonaton Ray, Jee H. Kim, Ivan B. Lobov
  • Patent number: 10934349
    Abstract: The disclosure provides compositions, kits, and methods of using a GDF-8 inhibitor to increase lean muscle mass. In embodiments, a GDF-8 inhibitor is an antibody or antigen binding fragment thereof that specifically binds GDF-8. In embodiments, a method comprises providing an exercise regimen for the subject, and administering a composition comprising an effective amount of a GDF-8 inhibitor.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: March 2, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Robert C. Pordy, Xiaobing Qian, Stephen Donahue
  • Patent number: 10927178
    Abstract: The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates for the treatment of a disorder associated with CXCR4 function or expression (e.g., cancer), such as colon, RCC, esophageal, gastric, head and neck, lung, ovarian, pancreatic cancer or hematological cancers.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: February 23, 2021
    Assignee: PFIZER INC.
    Inventors: Shu-Hui Liu, Flavia Mercer Pernasetti, Wei-Hsien Ho
  • Patent number: 10928393
    Abstract: Methods of treating a subject having a cardiovascular disease, selecting a therapy for a subject having a cardiovascular disease, identifying a subject having a cardiovascular disease that will benefit or not benefit from exercise therapy, determining whether a subject having a cardiovascular disease should begin, continue, not begin, discontinue, or avoid exercise therapy, determining whether a subject having a cardiovascular disease should continue, discontinue, or avoid exercise therapy, reducing the risk of an adverse outcome (e.g., death) in a subject having a cardiovascular disease, and predicting the efficacy of exercise therapy in a subject having a cardiovascular disease. These methods include determining a level of soluble ST2 in a subject.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: February 23, 2021
    Assignee: Critical Care Diagnostics, Inc.
    Inventors: James V. Snider, Robert W. Gerwien
  • Patent number: 10927177
    Abstract: The present disclosure provides a pharmaceutical composition for preventing or treating a variety of diseases through c-Met activation in cells induced by the anti-c-Met antibody described herein which functions as a c-Met agonist. The current invention concerns a method for preventing or treating various diseases through c-Met activation by the anti-c-Met antibody described herein.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: February 23, 2021
    Assignee: Helixmith Co., Ltd
    Inventors: Seung Shin Yu, Jae-Gyun Jeong, Dongsik Kim, Juwon Shim
  • Patent number: 10925938
    Abstract: A vaccine construct comprising an antigenic PCSK9 peptide and an immunogenic carrier, and methods of using the same that are effective to lower blood cholesterol levels in a mammal and treat dyslipidemias and related disease states in a mammal without the frequency of administration required by passive immunity strategies.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: February 23, 2021
    Assignees: THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES, UNM Rainforest Innovations
    Inventors: Alan Remaley, John T. Schiller, Marcelo Amar, Bryce Chackerian
  • Patent number: 10913783
    Abstract: The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: February 9, 2021
    Assignee: H. LUNDBECK A/S
    Inventors: Maria-Cristina Loomis, Leon F. Garcia-Martinez, Benjamin H. Dutzar, Daniel S. Allison, Katherine Lee Hendrix, Ethan W. Ojala, Pei Fan, Jeffrey T. L. Smith, John A. Latham, Charlie Karasek, Jenny Mulligan, Michelle Scalley-Kim, Erica Stewart, Vanessa Lisbeth Rubin, Jens J. Billgren
  • Patent number: 10914745
    Abstract: The present invention provides biomarker-based methods for diagnosing stroke in a patient suspected of having suffered a stroke, and also for discriminating between ischemic stroke and transient ischemic attack. Substrates comprising probes for specific combinations of biomarkers useful in the methods of the invention are also described.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: February 9, 2021
    Inventors: John Lamont, Ivan McConnell, Peter Fitzgerald
  • Patent number: 10906955
    Abstract: The invention provides recombinant Roundabout Receptor 2 (ROBO2) proteins designed to bind SLIT ligands and prevent their binding to ROBO2 cell surface receptors. Also provided are methods for use of these recombinant ROBO2 proteins.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: February 2, 2021
    Assignees: Pfizer Inc., Boston Medical Center Corporation
    Inventors: Stephen Berasi, Janet Elizabeth Buhlmann, Nathan Higginson-Scott, Michael Shamashkin, Matthew Russo, Stefano V. Gulla, Zong Sean Juo, Sreekumar R. Kodangattil, Weining Lu, Xueping Fan, David J. Salant
  • Patent number: 10898523
    Abstract: The present invention provides methods or kits with inflammatory cytokines to pretreat 1-ISCs to augment their immune modulatory effect, in prevention and treatment of various diseases such as multiple sclerosis, arthritis, lupus, sepsis, hepatitis, cirrhosis, Parkinson's disease, chronic infections, and GvHD. The present invention relates to novel methods for enhancing the immunosuppressive or the immune stimulatory activities of mesenchymal stem cells (JvfSCs).
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: January 26, 2021
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Yufang Shi, Guangwen Ren, Liying Zhang
  • Patent number: 10900040
    Abstract: Embodiments of the disclosure encompass methods and/or compositions for ameliorating or preventing intimal damage caused by mechanical stimulation of endothelial cells. The damage may be caused by use of a device within an artery, vein, or capillary of an individual, such as to remove a thrombus, an embolus or an atherosclerotic plaque in the vessel. Treatment and prevention embodiments concern therapeutically effective amounts of one or more antagonists of the SUR1-TRPM4 channel that is upregulated upon the mechanical stimulation.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: January 26, 2021
    Assignees: University of Maryland, Baltimore, The United States of America as Represented by the Department of Veterans Affairs, Biogen Chesapeake, LLC
    Inventors: J. Marc Simard, Sven Jacobson
  • Patent number: 10899834
    Abstract: The present invention is directed to antagonistic antibodies and antigen binding fragments thereof having binding specificity for PACAP. These antibodies inhibit, block or neutralize at least one biological effect associated with PACAP, e.g., vasodilation. In exemplary embodiments these antibodies and antigen binding fragments thereof may comprise specific VH, VL, and CDR polypeptides described herein. In some embodiments these antibodies and antigen binding fragments thereof bind to and/or compete for binding to specific epitope(s) on human PACAP. The invention is further directed to using these antagonistic anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, mast cell degranulation, and/or neuronal activation, are therapeutically beneficial, e.g., headache and migraine indications.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: January 26, 2021
    Assignee: H. LUNDBECK A/S
    Inventors: Maria-Cristina Loomis, Leon F. Garcia-Martinez, Benjamin H. Dutzar, Daniel S. Allison, Katherine Lee Hendrix, Ethan W. Ojala, Pei Fan, Jeffrey T. L. Smith, John A. Latham, Charlie Karasek, Jenny Mulligan, Michelle Scalley-Kim, Erica Stewart, Vanessa Lisbeth Rubin, Jens J. Billgren
  • Patent number: 10882904
    Abstract: The present invention relates to antibodies that specifically bind pro-myostatin and/or latent myostatin, and methods and uses thereof.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: January 5, 2021
    Assignee: Scholar Rock, Inc.
    Inventors: Adriana Donovan, Michelle Straub, Stefan Wawersik
  • Patent number: 10870689
    Abstract: The present disclosure is directed to an engineered phospholipid or lysophospholipid (e.g., sphingosine 1-phosphate (S1P)) chaperone derived from an Apolipoprotein M (ApoM)-Fc fusion protein having an extended half life in vivo. The disclosed ApoM-Fc fusion protein provides a safe, efficient and effective means of delivering S1P to endothelial cells and to all tissues of the body.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: December 22, 2020
    Assignee: The Children's Medical Center Corporation
    Inventors: Timothy T. Hla, Steven L. Swendeman, Annarita DiLorenzo, Teresa Sanchez
  • Patent number: 10870698
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: December 22, 2020
    Assignee: Novartis AG
    Inventors: Kurt Alex Heldwein, Igor Splawski, Jennifer Brogdon, Joshua Goldstein, William Dole, John Trauger, Chonghui Zhang
  • Patent number: 10858422
    Abstract: Described herein are peptides and antibodies for prevention and/or therapeutic treatment of mammals, including humans, against systemic lupus erythematosus, as well as diagnosing the presence or absence of antibodies related to increased or decreased risk of developing SLE and/or to disease grading, staging, and/or prognosis.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: December 8, 2020
    Assignee: Abcentra, LLC
    Inventors: Jan Nilsson, Ryan Benjamin Abbott, Bertrand C. Liang, Christopher John Farina, Stacey Ruiz